Document Detail


M-118, a novel, low-molecular-weight heparin for the potential treatment of cardiovascular disorders.
MedLine Citation:
PMID:  20730701     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Safe inhibition of thrombosis is a key therapeutic strategy in modern cardiovascular medicine, and both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used in clinical practice. However, both have several drawbacks, such as the unpredictable pharmacokinetics of UFH and the non-reversibility of LMWH. M-118, being developed by Momenta Pharmaceuticals Inc, is a novel LMWH that has been engineered to overcome the drawbacks of UFH and currently available LMWHs, while maintaining their beneficial attributes. In preclinical studies and phase I clinical trials, M-118 demonstrated potent activity against thrombin and Factor Xa, which could be reversed with protamine; M-118 also demonstrated a high and predictable bioavailability, and a short half-life. Promising results were observed in a phase II clinical trial in patients undergoing coronary interventions, although phase III clinical trials are required to establish the role for M-118 in contemporary medicine.
Authors:
Hriday Shah; Hitinder S Gurm
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  11     ISSN:  2040-3429     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-23     Completed Date:  2011-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1059-65     Citation Subset:  IM    
Affiliation:
University of Michigan, Division of Cardiovascular Medicine, 2A394, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5853, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Cardiovascular Diseases / drug therapy*
Clinical Trials as Topic
Dogs
Drug Evaluation, Preclinical
Heparin, Low-Molecular-Weight / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Humans
Male
Mice
Mice, Knockout
Rabbits
Rats
Thrombin / antagonists & inhibitors
Thrombosis / drug therapy
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/M-118 compound; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for t...
Next Document:  Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pu...